tafasitamab FDA approval on July 31, 2020, provides hope for patients with limited treatment options, though ongoing studies are necessary to fully understand its long-term efficacy and safety.

Ubix Therapeutics and Yuhan unveil an exclusive licensing deal for UBX-103, an oral AR degrader to treat metastatic castration-resistant prostate cancer.

Approved by the FDA on July 24, 2020, it utilizes innovative CAR-T cell technology to target and eliminate cancer cells, although it comes with significant risks and side effects that require careful management by healthcare professionals.

The European Union has approved the world's first Sanofi and Regenerant drug, dulprizumab, targeting IL-4Rα for COPD treatment.

on August 12, 2021, the FDA expanded its approval to include the treatment of idiopathic hypersomnia (IH) in adults.

Jul 4th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The U.S. Food and Drug Administration (FDA) approved Inqovi on July 7, 2020, for the treatment of certain types of myelodysplastic syndromes (MDS).

Pierre Fabre Laboratories have received European marketing approval for OBGEMSA™ (vibegron) to treat overactive bladder.

Jul 3rd latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

KBio Receives FDA IND Approval for EV68-228-N to Treat Acute Flaccid Myelitis and Begins Phase 1 Trial with First Patient Dosed.

The U.S. Food and Drug Administration (FDA) approved Rukobia on July 2, 2020, for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection.

GT Biopharma Gets FDA Approval for IND Application for GTB-3650, an NK Cell Engager Targeting CD33+ Leukemia.